Targeting LOXL2 in decreasing tumor cell growth and metastasis has been well-documented in various tumors such as gastric cancer [14], pancreatic cancer [15], and cervical cancer [16]. This evidence concerns the gene LOXL2 and familial pancreatic carcinoma.